Brand name: Anti-Fungal (Pharmacy Action)
Anti-Fungal (Pharmacy Action) is a medicine containing the active ingredient(s) clotrimazole. On this page you will find out more about Anti-Fungal (Pharmacy Action), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: clotrimazole
Information for medicine and pack size:
Anti-Fungal (Pharmacy Action) 1% cream, 20 g
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
A broad spectrum antifungal for the topical treatment of fungal skin infections, including tinea, athlete's foot, ringworm, and candidal infections such as nappy rash.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance | White, smooth semi-solid cream. |
| Dosage Form | Cream |
| Route of administration | Topical |
| Medicine schedule |
20g: Pharmacy Medicine (Over the counter)
50g: Pharmacy Medicine (Over the counter)
|
There is one type of pack available.
Pack type 1
| Type | Tube |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 3 Years |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 April 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 310 results
Oral Thrush (Monoliasis, Oral Candidiasis, OC) | myVMC
Oral thrush (candidiasis) is a yeast infection that occurs in the mouth. It is caused by the fungus Candida albicans. Anti-fungals are used in treatment.
Read more on myVMC – Virtual Medical Centre website
Over-the-counter medicines | Therapeutic Goods Administration (TGA)
You can buy over-the-counter (OTC) medicines for self-treatment from pharmacies, with selected products also available in supermarkets
Read more on TGA – Therapeutic Goods Administration website
Griseofulvin - ACD
Griseofulvin is used to treat fungal infections of the scalp, skin and nails.
Read more on Australasian College of Dermatologists website
Dandruff - myDr.com.au
Dandruff is when your scalp sheds excessive amounts of larger-than-normal skin flakes. These flakes stick to the hair shafts, eventually falling on the collars and shoulders of clothes.
Read more on myDr website
Resolve Plus 1.0 Cream - myDr.com.au
Resolve Plus 1.0 Cream - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
SB 5B Capsules - myDr.com.au
SB 5B Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Voriconazole APOTEX Powder for infusion - myDr.com.au
Voriconazole APOTEX Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluconazole Claris Solution for infusion - myDr.com.au
Fluconazole Claris Solution for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Chemists' Own Amer-Fine Nail Lacquer - myDr.com.au
Chemists' Own Amer-Fine Nail Lacquer - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Ozole Capsules - myDr.com.au
Ozole Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 22 results
Antifungal agents for infants and children with invasive fungal infections | Cochrane
Invasive fungal infections are a significant problem for children whose immune system is not functioning properly. The majority of the children have cancer. Antifungal medications can be given when these children develop a fever (for example a fever occurring when the white cells or neutrophils are low during chemotherapy) or when an infection has been formally identified (as in candidaemia, candidiasis and invasive aspergillosis). The antifungal agents that were compared appear equally efficacious. Pooling the data from the few studies that were available suggest kidney damage was less likely with a lipid preparation of amphotericin B compared with conventional amphotericin B. It is reasonable to recommend a lipid preparation of amphotericin B, if cost permits. No significant differences have been observed in children when other antifungal agents have been compared. More studies in children evaluating available antifungal are required to further clarify any benefits with regard to the risk of dying, prospects of complete recovery and drug toxicities.
Read more on Cochrane (Australasian Centre) website
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients | Cochrane
Read more on Cochrane (Australasian Centre) website
Oral antifungal drugs for treating athlete's foot (tinea pedis) | Cochrane
Athlete's foot (tinea pedis) is a fungal infection of the feet that is easily spread and difficult to get rid of. This review compared different oral antifungal drugs (i.e. drugs taken by mouth), and it included 15 trials, involving 1438 participants. There are several different kinds of oral treatments, and the trials we found considered all the oral drugs used to treat athlete's foot. We found terbinafine and itraconazole to be more effective than placebo. And we found terbinafine to be more effective than griseofulvin. Griseofulvin is a treatment that was developed much earlier than the new treatments, such as terbinafine and itraconazole; these newer treatments tend to be most evaluated. Trials of other drugs were not large enough to show differences between them. All drugs had side-effects; gastrointestinal effects were the most common.
Read more on Cochrane (Australasian Centre) website
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients | Cochrane
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
Read more on Cochrane (Australasian Centre) website
Cyclosporine for treating rheumatoid arthritis | Cochrane
This review included three trials with a total of 318 patients. A statistically significant decrease in the number of tender and swollen joints was found for patients taking cyclosporine when compared to those taking placebo. Significant improvements in pain and function were also found for those patients taking cyclosporine. More side effects occurred in the cyclosporine group compared to the placebo group.
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in patients with cancer with antifungal drugs | Cochrane
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in patients with cancer with amphotericin B | Cochrane
Read more on Cochrane (Australasian Centre) website
Cyclosporine A for induction of remission in severe ulcerative colitis | Cochrane
Ulcerative colitis (UC) is a chronic inflammation of the large bowel. Symptoms include bloody diarrhea and abdominal pain. The disease can also have manifestations outside the bowel with involvement of the joints, skin, eyes and liver. While the 'first line' treatment for a severe attack of UC is usually steroids (either as pills or intravenously) the options for patients not responding to steroids are limited and include surgical removal of the large bowel. Cyclosporine A (CsA), a drug effective in preventing transplant organ rejection by suppressing the immune system, was tried in severe UC with encouraging results in the early 1990's. The aim of this review was to assess the effectiveness of CsA for severe UC. The literature search identified 36 studies. Only 2 studies were of high methodological quality and both support the use of CsA in UC patients with a severe attack. However, both studies were small (involving only 50 patients altogether) and limited in the length of follow-up (from a few weeks up to a year). There is limited evidence that cyclosporine is more effective than standard treatment for severe ulcerative colitis. The conclusion of the review is that while the data concerning the use of CsA in severe UC are encouraging, more studies are needed.
Read more on Cochrane (Australasian Centre) website
Prevention of fungal infections in cancer patients with amphotericin B or fluconazole | Cochrane
Read more on Cochrane (Australasian Centre) website
Prevention and treatment of fungal infections with nystatin in severely immunodepressed patients | Cochrane
Read more on Cochrane (Australasian Centre) website
